Cardiac imaging agent detects ischemia and MI in phase II trial

A phase II clinical trial found that the CardioPET imaging agent correctly identified ischemia in exercise and pharmacologic stress studies in patients with coronary artery disease. The diagnostic accuracy of CardioPET was similar to that of single-photon emission computed tomography (SPECT) imaging.

The results were presented at the American Society of Nuclear Cardiology annual meeting on Sept. 24 in Boca Raton, Florida. FluoroPharma Medical, which manufactures CardioPET, announced the results in a news release.

CardioPET, an F-18 labeled, modified fatty acid used in cardiac PET imaging, is not yet FDA-approved. FluoroPharma Medical is evaluating the use of CardioPET to identify patients who will benefit from PCI or revascularization, assess myocardial variability and evaluate coronary artery disease in patients who cannot exercise.

The study enrolled 24 patients who had abnormal findings for clinically indicated SPECT scans with technetium-labeled compounds, which are the standard test for non-invasive diagnosis of coronary artery disease.

Patients were given a single dose of CardioPET with a comparable exercise or pharmacologic stress test or when they were at rest. The researchers compared the SPECT and PET images to coronary angiography to assess diagnostic performance.

“In this study, the unique fatty acid signal for CardioPET was shown to detect both ischemia and myocardial infarction,” Gary Heller, MD, of Morristown Medical Center in New Jersey and one of the trial’s researchers, said in a news release. “We were particularly intrigued with abnormal CardioPET images in subjects who were injected at rest, yet still had evidence of CAD on angiography. This indicates that it may be feasible to find CAD without an exercise test, and certainly should be studied further.”

Tim Casey,

Executive Editor

Tim Casey joined TriMed Media Group in 2015 as Executive Editor. For the previous four years, he worked as an editor and writer for HMP Communications, primarily focused on covering managed care issues and reporting from medical and health care conferences. He was also a staff reporter at the Sacramento Bee for more than four years covering professional, college and high school sports. He earned his undergraduate degree in psychology from the University of Notre Dame and his MBA degree from Georgetown University.

Around the web

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Kate Hanneman, MD, explains why many vendors and hospitals want to lower radiology's impact on the environment. "Taking steps to reduce the carbon footprint in healthcare isn’t just an opportunity," she said. "It’s also a responsibility."